Literature DB >> 20591543

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Joseph G Dauner1, Yuanji Pan, Allan Hildesheim, Clayton Harro, Ligia A Pinto.   

Abstract

Human papillomavirus (HPV)-specific antibodies are proposed to be the correlate of protection afforded by HPV L1 virus-like particle (VLP) vaccines. Previous studies have characterized the systemic antibody response to immunization in terms of both the quantity and the ability to neutralize HPV. Here, we have adapted a generalized memory B cell ELISPOT to the HPV16 system and expanded the analysis of the systemic antibody response to include an avidity measurement of HPV L1 VLP-specific antibodies. We show the results of the memory B cell ELISPOT significantly correlated with IgG and neutralizing antibody titers, but not with the avidity measurement. This is the first comprehensive study to correlate a variety of humoral aspects potentially associated with protective immunity following vaccination with a HPV16 L1 VLP vaccine. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591543      PMCID: PMC2913111          DOI: 10.1016/j.vaccine.2010.06.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

3.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.

Authors:  Shane Crotty; Rachael D Aubert; John Glidewell; Rafi Ahmed
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

4.  Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.

Authors:  Monika Simmons; Kevin R Porter; Curtis G Hayes; David W Vaughn; Robert Putnak
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

6.  Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus.

Authors:  J Polanec; I Seppälä; S Rousseau; K Hedman
Journal:  J Clin Lab Anal       Date:  1994       Impact factor: 2.352

7.  Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.

Authors:  Nitya Nair; Hayley Gans; Linda Lew-Yasukawa; Andrea C Long-Wagar; Ann Arvin; Diane E Griffin
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

8.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

9.  Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Authors:  Philippe A Denoël; David Goldblatt; Isabel de Vleeschauwer; Jeanne-Marie Jacquet; Michael E Pichichero; Jan T Poolman
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

10.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  13 in total

Review 1.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

2.  Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.

Authors:  Ligia A Pinto; Timothy J Wilkin; Troy J Kemp; Martha Abrahamsen; Kimberly Isaacs-Soriano; Yuanji Pan; Jennifer Webster-Cyriaque; Joel M Palefsky; Anna R Giuliano
Journal:  Vaccine       Date:  2019-03-30       Impact factor: 3.641

3.  HPV - immune response to infection and vaccination.

Authors:  Margaret Stanley
Journal:  Infect Agent Cancer       Date:  2010-10-20       Impact factor: 2.965

4.  Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes.

Authors:  Blanche P Alter; Neelam Giri; Yuanji Pan; Sharon A Savage; Ligia A Pinto
Journal:  Vaccine       Date:  2013-12-02       Impact factor: 3.641

Review 5.  Alternative dosage schedules with HPV virus-like particle vaccines.

Authors:  Margaret A Stanley; Staci L Sudenga; Anna R Giuliano
Journal:  Expert Rev Vaccines       Date:  2014-07-07       Impact factor: 5.217

Review 6.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

7.  Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

8.  Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.

Authors:  Proscovia B Namujju; Lea Hedman; Klaus Hedman; Cecily Banura; Edward K Mbidde; Dennison Kizito; Romano N Byaruhanga; Moses Muwanga; Reinhard Kirnbauer; Heljä-Marja Surcel; Matti Lehtinen
Journal:  BMC Res Notes       Date:  2011-06-06

9.  Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.

Authors:  Anna Godi; Sara L Bissett; Elizabeth Miller; Simon Beddows
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

10.  Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial.

Authors:  Ligia A Pinto; Troy J Kemp; B Nelson Torres; Kimberly Isaacs-Soriano; Donna Ingles; Martha Abrahamsen; Yuanji Pan; Eduardo Lazcano-Ponce; Jorge Salmeron; Anna R Giuliano
Journal:  J Infect Dis       Date:  2016-08-10       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.